Clean Label Project to Showcase Latest Protein Powder Contaminant Study at Natural Products Expo West 2025
As consumers increasingly incorporate protein supplements into their wellness routines and turn to GLP-1s for weight management, Clean Label Project's research offers vital insights into ingredient sourcing, manufacturing practices, and potential risks tied to some of the market's most popular products.
Protein Investigation 2.0: Key Findings
Clean Label Project's analysis of 160 protein supplements, representing 83% of the market share, revealed:
- 77% of protein powders tested contained lead, with nearly half exceeding California's Prop 65 safety limits in one serving.
- Organic protein powders contained three times more lead and twice as much cadmium as non-organic varieties.
- Chocolate-flavored protein powders contained up to 110 times more cadmium than vanilla-flavored powders.
CLP's 'Clean Sixteen'
Clean Label Project is excited to unveil our 'Clean Sixteen' — a lineup of sixteen protein powders that tested non-detect for heavy metals in the 2024/2025 protein powder study. This achievement highlights that, with dedicated supply chain diligence, it's entirely possible to craft protein powders that are not only nutritious, affordable, and delicious but also low in heavy metals.
Visit Clean Label Project at Expo West 2025
'Protein powder plays a key role in the morning routines of those aiming to build muscle, shed weight, or enhance their healthy lifestyle,' said Jackie Bowen, Executive Director of Clean Label Project. 'Consumers have a right to transparency about the products they rely on for their health. At Expo West, we're excited to explore how brands can elevate safety standards, refine sourcing practices, and restore consumer trust.'
Booth #3195 – Stop by to learn more about Clean Label Project's certification programs, industry advocacy efforts, and the latest contaminant testing insights.
For more information on Clean Label Project's latest research and initiatives, visit www.cleanlabelproject.org.
About Clean Label Project
Clean Label Project is a nonprofit organization dedicated to promoting truth and transparency in consumer product labeling and ingredient quality. Through independent testing for industrial and environmental contaminants, Clean Label Project provides consumers with the data they need to make informed, healthier choices.
Kate Stuard
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Mom's Urine Turns Black After Taking Weight-Loss Meds to Slim Down Before Vacation: ‘I Thought I Could Die'
NEED TO KNOW A Scottish mom of two bought a GLP-1 medication online to lose weight for a vacation, saying she was 'fed up with not fitting in my clothes' Claire Reed, 49, caims the medication made her too nauseous to eat or drink, and was so dehydrated 'my urine was black' Her children brought her to the hospital after she passed out, and says 'I thought I could die'A mom became so dehydrated while taking weight-loss medication she bought online that her urine turned black, leading to her being hospitalized and fearing for her life. Claire Reed, 49, was planning a vacation with her daughter, and admitted 'I was fed up with not fitting in my clothes,' according to Daily Mail. Although the mom of two, who hails from the Scottish city of Aberdeen, says she wasn't 'that big' — she was classified as overweight, not obese — she decided to buy weight-loss medication via an online pharmacy in March. She didn't see a doctor; Rather, she just filled out an online questionnaire. When she received the medication, she admitted, 'There were no instructions on how to deal with it.' In the first few months of taking the medication, Claire says she lost nearly 60 lbs. But as time went on, she began to feel nauseous every time she ate or drank — would sporadically lose consciousness. 'I couldn't eat, so I was just collapsing because I had no food or water. I wasn't able to process anything in my body. I felt very sick and had no appetite,' Claire says. 'I was never going to the toilet and when I did my urine was black. I had to force myself to drink water.' She says she was "embarrassed," and hid her struggles from her family and friends. It wasn't until she had an episode in front of her son and daughter that her children began 'panicking' and took their mother for urgent medical care. 'They put me on an IV. I told them I've been taking the jab and they said this could be what it is,' Claire said, sharing that the doctors cautioned her about online pharmacies. 'The people selling it to you can't see you, they're just asking a quick questionnaire. And then you're left on your own.' She's stopped taking the medication, but says she's struggled to regain any appetite. 'I'm still not hungry and still not gaining weight. Any food at all makes me feel sick,' Claire said. 'I was very scared, your body needs food and fluid. I thought I could die.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Read the original article on People
CNBC
5 hours ago
- CNBC
Eli Lilly earnings are coming Thursday. Here's what top analysts expect
Many on Wall Street expect that Novo Nordisk 's loss has been Eli Lilly 's gain, and this will be good news for the Zepbound maker's second-quarter results. Novo Nordisk's stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and Wegovy for obesity. The company has said its business has been hurt by competition from compounding pharmacies, which are making knock-off versions of its semaglutide, the active ingredient in both brands. This prompted Novo to cut its annual forecast and oust its CEO. Lilly's business appears to be holding up much better, according to analysts. They anticipate the proof will be in the quarterly results and outlook. What's more, several analysts expect other catalysts, including next-generation drugs, to help propel Lilly shares higher. 'Potential materiality' So far this year, Lilly's stock has logged a roughly 3% decline, underperforming the market. However, catalysts could come as soon as Thursday, analysts say. "We note that LLY's upcoming 2Q call is scheduled for 8:30am ET on Aug 7th, as opposed the company's standard 10am ET time slot for earnings calls after the market opens, suggesting potential materiality via topline trial results alongside earnings," Goldman Sachs analyst Asad Haider wrote in a July 28 research note. He said the report is "the most highly anticipated near-term event" across his pharmaceutical coverage. In addition to the financial outlook, investors are eager to hear more about orforglipron , the company's experimental GLP-1 pill. In June, at the American Diabetes Association conference, Lilly revealed the drug helped patients with type 2 diabetes in a late-stage trial lose weight without serious side effects . The readout of the phase 3 data for patients with obesity should be released soon. Wegovy's 'favored status' Analysts are also eager to hear management's thoughts on CVS Health 's policy of giving favored status to Wegovy over Lilly's Zepbound. The policy went into effect in July and means CVS Health's pharmacy benefit manager Caremark will prioritize Wegovy on its list of covered drugs. It has the potential to be a headwind for Lilly. However, patients may seek exemptions and remain on the weight loss drug or pay out of pocket on their own or via Lilly Direct, the company's direct-to-consumer website. Also, there is the possibility Lilly will strike a deal and get back on CVS Caremark's list of covered medications, analysts said. According to Bernstein analyst Courtney Breen, the first few weeks of the switch showed that patients changing from Zepbound to Wegovy was eclipsed by the number of patients starting the drug with a new prescription. On average, analysts surveyed by LSEG expect Lilly will earn $5.57 per share in the second quarter on revenue of $14.71 billion. If Lilly hits that revenue estimate, it will have achieved 30% growth year over year. Here's what else they're saying ahead of the report. LLY YTD mountain Eli Lilly shares year to date. Citigroup: Buy rating, $1,190 price target Citi analyst Geoff Meacham said Lilly remains one of its favorite stocks, and he placed a 90-day catalyst watch on it on July 30. His $1,190 price target implies 55% upside from Tuesday's close. "GLP-1 script data from IQVIA give us continued confidence in achievability of Lilly's 2025 revenue guidance ($58B-$61B). Notably, Zepbound scripts remain robust (+45% q/q) and overall share increased to 65.5%, representing a gain of ~600bps in market share. We think this is particularly noteworthy given vials from LillyDirect now represent ~20% of TRx [total prescriptions] and highlight increasing potential for a consumer angle in GLP-1 sales … driving uptake going forward (2Q25e $3.1B; +$99M vs. BBG cons). [Type 2 diabetes drug] Mounjaro scripts rose 16.3% q/q and now captures 42.2% share (2Q25e $4.5B; +$18M vs. cons); though slower growth than Zepbound, this is expected given the more entrenched nature of the type 2 diabetes market. … Top of mind for investors will be orforglipron's phase 3 ATTAIN readouts for obesity (Jul/Aug). Weight loss of 12-15% is the efficacy bar and continuation of a squeaky-clean safety profile that we saw at ADA for ACHIEVE … will be paramount." Morgan Stanley: Overweight, $1,135 In early July, Morgan Stanley analyst Terence Flynn tweaked his price target, increasing it to $1,135 from $1,133. The target suggests 48% upside. "In our view the magnitude of potential Mounjaro+Zepbound 2Q beat will dictate how LLY handles 2025 revenue guidance of $58-$61bn (MS $62.3bn vs. Cons $59.8bn), but we expect a raise of the low end at a minimum. LLY could also release Orfor Ph3 obesity and/or SURPASS-CVOT data in conjunction with earnings. … Interim Ph3 data for LLY's Kisunla in preclinical Alzheimer's (potentially later this year) could be a de-risking event for treating earlier in the disease course and expand the opportunity for the category, as well as provide lateral read-through to BIIB/Eisai's Leqembi (where Ph3 is also ongoing)" Bernstein: Outperform, $1,100 Bernstein, Wells Fargo and JPMorgan all have a $1,100 price target for Lilly's stock, which suggests it could rise nearly 44% from Tuesday's close. "We again see the potential for a meet or beat … , driven by Mounjaro & Zepbound performance. Given most of the street follow scripts closely in the US, the upside here arises from additional unexpected pricing (rebate adjustments), underreporting in IQVIA (a possibility), and ex-US performance (due to lower visibility). … Despite the potential for a top-line beat (we see potential for modest 1.2% beat above consensus at 14.6B), we don't anticipate LLY will be rushing to increase guidance, given last years back half challenges and the uncertainty for Q3 that remains on CVS caremark (although initial signs look strong)." Wells Fargo: Overweight, $1,100 "NVO lowering their guidance on Ozempic and Wegovy headwinds could be limited to NVO itself, as they cite continued compounding, competition, and slower market expansion. We believe LLY guidance can be raised on strong underlying trends. … Therefore, we would be buyers of LLY on the weakness since we expect a strong 2Q and a catalyst-rich 2H'25." JPMorgan: Overweight, $1,100 "Overall, we are expecting a solid 2Q for LLY with upside to Mounjaro/Zepbound (based on strong TRx growth trends), and we estimate total sales in the qtr of $14.8bn (+$370mm vs cons). On the EPS line, we are slightly below consensus ($5.49, -$0.06) as we expect a continued opex ramp to support a growing late stage pipeline and [direct-to consumer] initiatives. Looking forward, we expect some moderation in Zepbound growth as the CVS formulary change takes effect on July 1 but expect the product to still grow TRx in 3Q and accelerate in 4Q. And for the year, our estimates are near the high end of the company's 2025 guidance on both topline ($60.8bn sales, +$1.3bn vs cons) and the bottomline ($22.09 EPS, +$0.07 vs cons) and we would not be surprised to see LLY raise guidance at some point in 2025 (although the company may take a more conservative approach on the timing/magnitude of the increases given 2024 guidance dynamics)." Goldman Sachs: Buy, $883 Haider's $883 price target is about 15% above where Lilly shares closed on Tuesday. " … we expect another revenue beat, driven by an [foreign exchange] tailwind and strong TRx growth for Zepbound/Mounjaro where our and consensus estimates have tracked higher into the print. ... Into the 2Q earnings call, we also note significant investor discussion on the magnitude of potential upward pressure on the company's FY25 revenue guidance where we expect management could tighten the range of $58-$61bn for the year by bumping up the low-end (based on 1H trends, GS/consensus estimates are $60bn/$60.6bn for 2025). These trends are now well-understood with investor focus higher on trying to triangulate the impact to 3Q25 sales for Zepbound/Mounjaro from the CVS formulary change in favor of Novo that took effect on July 1st."
Yahoo
5 hours ago
- Yahoo
Ozempic May Help Prevent This Medical Emergency, According To New Research
You've probably heard by now that Ozempic may do much more than *just* help you lose weight and manage your blood sugar. Along with lowering the risk of Alzheimer's disease, tamping down PCOS symptoms, and combating a slew of other serious health conditions, three new studies suggest that the medication could help prevent and treat stroke. It may seem like a random link, but doctors say it actually makes a lot of sense. We tapped two neurologists and a doctor who prescribes Ozempic for more details. Meet the experts: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA; Amit Sachdev, MD, is the medical director in the Department of Neurology at Michigan State University; Mir Ali, MD, is medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA What do the studies say? All three studies were recently presented at the Society of NeuroInterventional Surgery's annual meeting, and they have a common theme. The first was published in the Journal of NeuroInterventional Surgery. For the study, researchers analyzed data from a global database and a database from the University of Wisconsin, looking at more than 2 million people who had a stroke. Of those, nearly 44,000 were also on Ozempic. The researchers found that people who took Ozempic were less likely to die from stroke, and the differences were huge. In the global database, 5.26 percent of Ozempic users initially died from their strokes, compared to 21.6 percent of those who didn't take the medication. The University of Wisconsin group had similar results: 5.26 percent of Ozempic users died from stroke compared to 26.6 percent of those who didn't take the medication. The next study was also published in the Journal of NeuroInterventional Surgery. It looked at ER records for people who had a stroke and those who were likely using Ozempic. (The researchers looked at medical codes that usually suggest a patient is on Ozempic, but couldn't definitively say they were taking the medication.) The researchers found that people who likely used Ozempic had both a lower risk of stroke and a lower risk of dying from any cause compared to those who didn't take the medication. For the final study, researchers analyzed patient records from six months and 12 months after people had a brain hemorrhage, and a year and two years after having a stroke. The researchers discovered that people who used a GLP-1 receptor agonist medication like Ozempic had a lower risk of cognitive side effects, seizures, future brain bleeds, and death after a brain hemorrhage and stroke. Why might Ozempic help prevent or treat stroke? All of these studies found a link between people who took Ozempic and a lower risk of having stroke or serious complications from a stroke. But it's important to point out that they didn't prove taking Ozempic will have this effect. That said, there are a few reasons why Ozempic may have this impact. It could simply be tied to weight, says Amit Sachdev, MD, medical director in the Department of Neurology at Michigan State University. 'Obesity is a major risk factor for cardiovascular health,' he says. 'Reducing excess weight is expected to have a clear and positive impact on overall health, including cardiovascular health.' Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA, agrees. 'Lowering a person's weight lowers a person's fats circulating through their blood or their lipid level,' he explains. 'High lipid levels, or fats, circulating through your blood can cause clogged pipes in your brain or an ischemic stroke.' But Ozempic and other GLP-1 receptor agonists also help improve a range of health conditions that are linked with stroke, points out Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA. 'It's hard to say if this is due to improvement in blood sugar control, weight loss, or other health conditions,' he says. More ways to lower your risk of stroke Taking Ozempic isn't for everyone, and doctors stress that we're not quite there yet with actually recommending the medication to lower your risk of stroke. If you want to lower your risk of stroke, the Centers for Disease Control and Prevention (CDC) recommends taking these steps: Focus on your diet. That means eating plenty of fruits and vegetables, and minimizing foods high in saturated fats, trans fat, sodium, and cholesterol. Try to maintain a healthy weight. Being overweight or having obesity increases the risk of stroke, Dr. Ali points out. Move regularly. Getting at least 2.5 hours of moderate-intensity physical activity can help. Don't smoke. Smoking is a big risk factor for stroke. Limit . Men should have no more than two drinks a day, while women should have no more than one, per the CDC. However, doctors generally recommend having even less. Do your best to manage underlying health conditions. That includes cholesterol, diabetes, blood pressure, and heart disease—all of which are risk factors for stroke. Of course, if you have a family history of stroke or personal risk factors, it's important to talk to a healthcare professional. They can offer personalized guidance to help keep you healthy. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
